- Adherium (ADR) enters into a trading halt pending a capital raise announcement
- The company is planning to launch a placement to sophisticated and professional investors but did not give details on to how much it was looking to raise
- Trading of ADR shares will be paused until September 16 or until the company releases further details
- Shares last traded at 0.8 cents on September 9
Respiratory eHealth company Adherium (ADR) has entered into a trading halt pending a capital raise announcement.
The company is planning to launch a placement to sophisticated and professional investors but did not give details on to how much it was looking to raise.
It also did not say what the funds will be used for.
Trading of ADR shares will be paused until September 16 or until the company releases further details.
In June, the company had signed its first UK distribution deal with Helicon Health to sell the Hailie sensor range and cloud data services.
The Hailie platform provides clinicians, healthcare providers and patients access to remotely monitored medication usage guidelines.
It attaches to an asthma or chronic obstructive pulmonary disease medication inhaler and connects to Helicon’s remote patient monitoring platform.
It was designed to provide visibility to healthcare providers of a patient’s medication use to better understand patterns in disease.
Shares last traded at 0.8 cents on September 9.